Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of Fecal Ribonucleic Acid (RNA) Test With Fecal Occult Blood Test (FOBT) for Detecting Colorectal Cancer and Adenoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by Hamamatsu University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Hamamatsu University
ClinicalTrials.gov Identifier:
NCT00197405
First received: September 12, 2005
Last updated: August 3, 2009
Last verified: August 2009
  Purpose

Colorectal cancer (CRC) is the second common cause of death in the Western world, and is very increasing in Japan. Fecal occult blood test (FOBT) is used routinely for CRC screening, which has been shown to reduce the incidence, morbidity, and mortality of CRC. However, there is a need to develop a novel method to improve sensitivity. The investigators reported that Fecal COX-2 assay, one of fecal RNA test, is potentially useful for colorectal cancer screening (Gastroenterology 127; 422-427, 2004). So the investigators planed to compare fecal RNA test with FOBT for detecting colorectal cancer and adenoma.


Condition
Colorectal Cancer

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Comparative Study of Fecal RNA Test With Immunochemical Fecal Occult Blood Test for Detecting Colorectal Cancer and Adenoma

Resource links provided by NLM:


Further study details as provided by Hamamatsu University:

Biospecimen Retention:   Samples Without DNA

freces, biopsy tissue samples


Estimated Enrollment: 400
Study Start Date: August 1999
Estimated Study Completion Date: December 2010
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

outpatients and inpatients of hospitals, subjects of parimary care clinics

Criteria

Inclusion Criteria:

  • Clinical diagnosis of colorectal cancer or adenoma
  • Subjects with no abnormal findings of colon
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00197405

Locations
Japan
Hamamatsu University School of Medicine Recruiting
Hamamatsu, Japan, 431-3192
Contact: Shigeru Kanaoka, M.D.    81-53-435-2261    kanaoka@hama-med.ac.jp   
Principal Investigator: Shigeru Kanaoka, M.D.         
Sponsors and Collaborators
Hamamatsu University
Investigators
Study Chair: Shigeru Kanaoka, M.D.
  More Information

No publications provided

Responsible Party: Shigeru Kanaoka, Hamamatsu University School of Medicine
ClinicalTrials.gov Identifier: NCT00197405     History of Changes
Other Study ID Numbers: CRC-FRT-001
Study First Received: September 12, 2005
Last Updated: August 3, 2009
Health Authority: Japan: Ministry of Health, Labor and Welfare

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases

ClinicalTrials.gov processed this record on November 27, 2014